Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Evaluation of Adherence With Bisphosphonates and Calcium and Vitamin D Supplements in Women With Postmenopausal Osteoporosis

Observational, Cross-sectional, Multicenter Study to Evaluate Adherence to Different Treatment Regimens With Oral Bisphosphonates and Calcium and Vitamin D Supplements in Postmenopausal Osteoporosis.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study aims to evaluate the adherence of patients to combined treatment with bisphosphonates and calcium and vitamin D supplements, which is one of the usual treatments for postmenopausal osteoporosis. The study will consist of a single visit that will coincide with one of the patient's usual follow-up visits according to standard clinical practice. During this visit, information will be collected from the patient's medical history and an interview will be conducted using 3 questionnaires to assess how and how often the patient takes the treatment, possible forgetfulness, and whether or not the patient is satisfied with their current treatment.

Who May Be Eligible (Plain English)

Who May Qualify: 1. \- Women diagnosed with postmenopausal OP. 2. \- Women who had been prescribed oral treatment with a BP administered monthly or weekly together with a Ca/D supplement (sachets or chewable tablets) administered daily, at least 6 months prior to inclusion in the study. 3. \- Women who had given their written willing to sign a consent form before participating in the study. Who Should NOT Join This Trial: None Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. \- Women diagnosed with postmenopausal OP. 2. \- Women who had been prescribed oral treatment with a BP administered monthly or weekly together with a Ca/D supplement (sachets or chewable tablets) administered daily, at least 6 months prior to inclusion in the study. 3. \- Women who had given their written informed consent before participating in the study. Exclusion Criteria: None

Locations (20)

Clinica Gaias Santiago
Santiago de Compostela, A coruña, Spain
CP Dr Caracuel
Córdoba, Andalusia, Spain
Hospital Reina Sofia
Córdoba, Andalusia, Spain
Hospital Virgen del Rocio
Seville, Andalusia, Spain
CP Dr Agramonte
Palma de Mallorca, Balearic Islands, Spain
CP Dr Balta
Palma de Mallorca, Balearic Islands, Spain
CHU Insular - H Materno-Infantil
Las Palmas de Gran Canaria, Canary Islands, Spain
CHU Insular - H Materno-Infantil
Las Palmas de Gran Canaria, Canary Islands, Spain
Hospital Zamora
Zamora, Castille and León, Spain
Clinica Sagrada Familia
Barcelona, Catalonia, Spain
CP Dra Sanchez
Barcelona, Catalonia, Spain
Hospital del Mar
Barcelona, Catalonia, Spain
Hospital del Tajo
Aranjuez, Madrid, Spain
CP Dr Solano
Madrid, Madrid, Spain
CP Dr Zafra
Madrid, Madrid, Spain
CP Dra Gerechter
Madrid, Madrid, Spain
Hospital Infanta Leonor
Madrid, Madrid, Spain
Hospital Virgen del Mar
Madrid, Madrid, Spain
CP Dr Larrauri
Vigo, Pontevedra, Spain
CP Dra Medrano
Alicante, Valencia, Spain